18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours

Nuclear Medicine Communications

Volumn 33, Issue 2, 2012, Pages 179-184

  Chondrogiannis, Sotirios ^a   Grassetto, Gaia ^a   Marzola, Maria Cristina ^a   Rampin, Lucia ^a   Massaro, Arianna ^a   Bellan, Elena ^b   Ferretti, Alice ^a,b   Mazza, Alberto ^b   Al Nahhas, Adil ^c   Rubello, Domenico ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b Santa Maria della Misericordia Hospital Rovigo   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

biodistribution; L 6 fluoro 3,4 dihydroxyphenylalanine PET CT; neuroendocrine tumours; physiologic pattern

Indexed keywords

6 FLUORODOPA F 18; DOPA; DRUG DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BASAL GANGLION; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; PANCREAS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; SCHOOL CHILD; THYROID MEDULLARY CARCINOMA; VON HIPPEL LINDAU DISEASE; IMAGE ENHANCEMENT; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; TISSUE DISTRIBUTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84855187804     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834e0974     Document Type: Article

References (24)

1. Nanni C, Fantini L, Nicolini S, Fanti S. Non FDG PET. Clin Radiol 2010; 65:536-548.
2. Kauhanen A, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of 18Ffluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 2009; 16:255-265.
3. Fluorodopa F18 (Systemic). Available at http://www.drugs.com. Accessed 1999.
4. 18FFluoro-L-DOPA and its metabolism in vivo: critical review. Int J Rad Appl Instrum B 1992; 19:149-158.
5. 18FFluoro-L-DOPA for the in vivo study of intracerebral dopamine. Int J Rad Appl Instrum A 1986; 37:669-675.
6. Brouwers AH, Koopmans KP, RAJO Bierckx, Elsinga PH. DOPA PET/CT. In: Fanti S, Farsad M, Mansi L, editors. PET/CT Beyond FDG: a quick guide to image interpretation, Chapter 10. Heidelberg: Springer; 2010. pp. 161-179.
7. 18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008; 49:573-586. (Pubitemid 351520605)
8. Caroli P, Nanni C, Rubello D, Alavi A, Fanti S. Non-FDG PET in the practice of oncology. Indian J Cancer 2010; 47:120-125.
9. 18FFDOPA and issue concerning its quality analyses as in USP 'Fluorodopa F 18 Injection'. Ann Nucl Med 2011; 25:309-316.
10. Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol 2010; 36:414-421.
11. Taieb D, Rubello D, Al-Nahhas A, Calzada M, Marzola MC, Hindié E, et al. Modern PET imaging for paragangliomas: relation to genetic mutation. Eur J Surg Oncol 2011; 37:662-668.
12. Schiesser M, Veit-Haibach P, Muller MK, Weber M, Bauerfeind P, Hany T, et al. Value of combined 6-18F fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours. Br J Surg 2010; 97:691-697.
13. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010; 20:527-533.
14. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008; 49:524-531. (Pubitemid 351520599)
15. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging 2010; 37:484-493.
16. Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 2009; 19:1425-1434.
17. Arbizu J, Rodriguez-Fraile M, Dominguez-Prado I, Garrastachu P, Rotellar F, Sangro B, et al. Whole body 18fluoro-L-dopa PET-CT: a useful tool for location and surgical guidance in primary carcinoid tumours. Eur J Nucl Med Mol Imaging 2008; 35:1577.
18. Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 2010; 95:2800-2810.
19. Grassetto G, Massaro A, Cittadin S, Padoan A, Manara R, d'Avella D, et al. Kinetic of 18F-DOPA in basal ganglia of non-human primate. Eur J Nucl Med Mol Imaging 2009; (Suppl 2):145-539.
20. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009; 94:4757-4767.
21. Täieb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol 2008; 69:580-586.
22. Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009; 36:765-770.
23. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35:1431-1438.
24. Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 2010; 31:1025-1032.